
ACOG Stock Forecast & Price Target
ACOG Analyst Ratings
Bulls say
Alpha Cognition Inc., a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, is positioned for significant sales growth driven by its ZUNVEYL oral tablet formulation. The company anticipates meaningful sales advancements as it implements contracting strategies and expands outreach efforts, particularly aiming at neurologists beyond long-term care facilities starting next year. With a projected year-end cash balance of approximately $63 million in 2025, it is expected that Alpha Cognition will have sufficient resources to support operations until it reaches profitability.
Bears say
Alpha Cognition Inc's negative outlook is underscored by a significant revision of the full-year 2025 net sales forecast, which has been decreased from $11.7 million to $5.7 million, reflecting anticipated challenges in contracting and reimbursement processes. Additional risks impacting the company's performance include potential delays in the launch of its lead product ZUNVEYL, slower market uptake due to competitive pressures and pricing issues, and the possibility of setbacks in clinical development. Furthermore, there exists a concern regarding medium- to long-term dilution risk, which could negatively affect investor confidence and the company's financial stability.
This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.
ACOG Analyst Forecast & Price Prediction
Start investing in ACOG
Order type
Buy in
Order amount
Est. shares
0 shares